BCRX
Income statement / Annual
Last year (2023), BioCryst Pharmaceuticals, Inc.'s total revenue was $331.41 M,
an increase of 22.37% from the previous year.
In 2023, BioCryst Pharmaceuticals, Inc.'s net income was -$226.54 M.
See BioCryst Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$331.41 M
|
$270.83 M
|
$157.17 M
|
$17.81 M
|
$48.84 M
|
$20.65 M
|
$25.19 M
|
$26.35 M
|
$48.26 M
|
$13.61 M
|
| Cost of Revenue |
$6.32 M |
$6.59 M |
$7.26 M |
$1.68 M |
$4.10 M |
$471,000.00 |
$1.70 M |
$2.70 M |
$1.90 M |
$122,000.00 |
| Gross Profit |
$325.10 M |
$264.23 M |
$149.91 M |
$16.14 M |
$44.73 M |
$20.18 M |
$23.48 M |
$23.65 M |
$46.36 M |
$13.49 M |
| Gross Profit Ratio |
0.98 |
0.98 |
0.95 |
0.91 |
0.92 |
0.98 |
0.93 |
0.9 |
0.96 |
0.99 |
| Research and Development
Expenses |
$216.57 M
|
$253.30 M
|
$208.81 M
|
$122.96 M
|
$107.07 M
|
$84.89 M
|
$66.96 M
|
$61.01 M
|
$72.76 M
|
$51.80 M
|
| General & Administrative
Expenses |
$199.49 M
|
$144.48 M
|
$113.11 M
|
$61.36 M
|
$0.00
|
$29.51 M
|
$13.93 M
|
$11.25 M
|
$13.05 M
|
$7.46 M
|
| Selling & Marketing
Expenses |
$14.40 M
|
$14.89 M
|
$5.71 M
|
$6.57 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$213.89 M
|
$159.37 M
|
$118.82 M
|
$67.93 M
|
$37.12 M
|
$29.51 M
|
$13.93 M
|
$11.25 M
|
$13.05 M
|
$7.46 M
|
| Other Expenses |
$0.00 |
$253.27 M |
$202.92 M |
$111.96 M |
$82.44 M |
$70.81 M |
$54.38 M |
$47.01 M |
$33.71 M |
$41.37 M |
| Operating Expenses |
$218.47 M |
$412.67 M |
$327.63 M |
$190.89 M |
$144.19 M |
$114.40 M |
$80.90 M |
$72.26 M |
$85.81 M |
$59.26 M |
| Cost And Expenses |
$435.12 M |
$419.26 M |
$334.89 M |
$192.57 M |
$148.29 M |
$114.87 M |
$82.60 M |
$74.96 M |
$87.70 M |
$59.38 M |
| Interest Income |
$15.78 M |
$5.13 M |
$62,000.00 |
$9.42 M |
$1.93 M |
$2.25 M |
$1.02 M |
$793,000.00 |
$535,000.00 |
$93,000.00 |
| Interest Expense |
$108.24 M |
$99.09 M |
$59.29 M |
$14.50 M |
$11.89 M |
$9.18 M |
$8.57 M |
$6.49 M |
$5.20 M |
$5.00 M |
| Depreciation &
Amortization |
$1.66 M
|
$1.44 M
|
$777,000.00
|
$748,000.00
|
$724,000.00
|
$770,000.00
|
$704,000.00
|
$483,000.00
|
$180,000.00
|
$177,000.00
|
| EBITDA |
-$116.34 M
|
-$143.85 M
|
-$121.74 M
|
-$167.57 M
|
-$96.28 M
|
-$90.37 M
|
-$56.51 M
|
-$48.17 M
|
-$37.64 M
|
-$40.01 M
|
| EBITDA Ratio |
-0.35 |
-0.53 |
-1.13 |
-9.28 |
-2 |
-4.45 |
-2.24 |
-1.81 |
-0.81 |
-3.36 |
| Operating Income Ratio
|
-0.31
|
-0.55
|
-1.13
|
-9.81
|
-2.04
|
-4.56
|
-2.28
|
-1.84
|
-0.82
|
-3.36
|
| Total Other
Income/Expenses Net |
-$122.52 M
|
-$95.95 M
|
-$4.09 M
|
-$8.06 M
|
-$9.44 M
|
-$7.03 M
|
-$8.37 M
|
-$6.54 M
|
-$3.58 M
|
$582,000.00
|
| Income Before Tax |
-$226.23 M |
-$244.38 M |
-$181.81 M |
-$182.81 M |
-$108.90 M |
-$101.25 M |
-$65.78 M |
-$55.14 M |
-$43.02 M |
-$45.19 M |
| Income Before Tax Ratio
|
-0.68
|
-0.9
|
-1.16
|
-10.26
|
-2.23
|
-4.9
|
-2.61
|
-2.09
|
-0.89
|
-3.32
|
| Income Tax Expense |
$310,000.00 |
$2.73 M |
$2.25 M |
$13.75 M |
$11.17 M |
$2.14 M |
$7.86 M |
$6.00 M |
$5.02 M |
$4.82 M |
| Net Income |
-$226.54 M |
-$247.12 M |
-$184.06 M |
-$196.57 M |
-$120.07 M |
-$101.25 M |
-$65.78 M |
-$55.14 M |
-$43.02 M |
-$45.19 M |
| Net Income Ratio |
-0.68 |
-0.91 |
-1.17 |
-11.04 |
-2.46 |
-4.9 |
-2.61 |
-2.09 |
-0.89 |
-3.32 |
| EPS |
-1.18 |
-1.33 |
-1.03 |
-1.18 |
-1.04 |
-0.98 |
-0.78 |
-0.75 |
-0.59 |
-0.68 |
| EPS Diluted |
-1.18 |
-1.33 |
-1.03 |
-1.18 |
-1.04 |
-0.98 |
-0.78 |
-0.75 |
-0.59 |
-0.68 |
| Weighted Average Shares
Out |
$192.20 M
|
$185.91 M
|
$179.12 M
|
$167.27 M
|
$115.60 M
|
$103.19 M
|
$84.45 M
|
$73.70 M
|
$72.90 M
|
$66.77 M
|
| Weighted Average Shares
Out Diluted |
$192.20 M
|
$185.91 M
|
$179.12 M
|
$167.27 M
|
$115.60 M
|
$103.19 M
|
$84.45 M
|
$73.70 M
|
$72.90 M
|
$66.77 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
